Table 1 Genetic characteristics of CRLF2-rearranged ALL cell line and patient-derived xenograft models utilized in these studies.

From: Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia

Xenograft model

COG USI

Disease status

CRLF2 rearrangement

Other genetic alterations

MUTZ5

n/a

newly-diagnosed Ph-like ALL

IGH::CRLF2

JAK2 R683G mutation

JH331

PAMDKS

newly-diagnosed Ph-like

IGH::CRLF2

CDKN2A, IKZF1, PAX5 deletions

ALL121

none

relapsed Ph-like ALL

IGH::CRLF2

CDKN2A/B deletion, JAK2 R683G mutation

DS-ALL47

PAUVIE

newly-diagnosed DS-ALL

P2RY8::CRLF2

JAK2 L730F, K926R, I951K mutations

DS-ALL515

PAWBHJ

relapsed DS-ALL

P2RY8::CRLF2

BTG1, CDKN2A/B, IKZF1, PAX5, PMS2, TCRG deletions

TCHK150

none

relapsed DS-ALL

IGH::CRLF2

JAK2 R867Q mutation, SCMH1::HMHB1, NR3C1::NWD2, C19orf60::ZCCHC7 fusions

  1. COG USI Children’s Oncology Group unique specific identifier, DS-ALL Down syndrome-associated acute lymphoblastic leukemia, n/a not applicable, Ph-like ALL Philadelphia chromosome-like acute lymphoblastic leukemia.
Back to article page